- Home
- HBT vs ZYME Comparison
HBT vs ZYME Comparison
Compare HBT & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBT
- ZYME
- Stock Information
- Founded
- HBT 1920
- ZYME 2003
- Country
- HBT United States
- ZYME United States
- Employees
- HBT N/A
- ZYME N/A
- Industry
- HBT Major Banks
- ZYME Biotechnology: Pharmaceutical Preparations
- Sector
- HBT Finance
- ZYME Health Care
- Exchange
- HBT Nasdaq
- ZYME Nasdaq
- Market Cap
- HBT 812.0M
- ZYME 968.5M
- IPO Year
- HBT 2019
- ZYME 2017
- Fundamental
- Price
- HBT $26.58
- ZYME $15.10
- Analyst Decision
- HBT Buy
- ZYME Buy
- Analyst Count
- HBT 5
- ZYME 7
- Target Price
- HBT $29.00
- ZYME $20.00
- AVG Volume (30 Days)
- HBT 32.3K
- ZYME 448.6K
- Earning Date
- HBT 10-20-2025
- ZYME 08-07-2025
- Dividend Yield
- HBT 3.34%
- ZYME N/A
- EPS Growth
- HBT 8.10
- ZYME N/A
- EPS
- HBT 2.42
- ZYME N/A
- Revenue
- HBT $229,851,000.00
- ZYME $122,867,000.00
- Revenue This Year
- HBT $8.74
- ZYME $44.71
- Revenue Next Year
- HBT $2.25
- ZYME $34.57
- P/E Ratio
- HBT $10.38
- ZYME N/A
- Revenue Growth
- HBT 4.61
- ZYME 95.94
- 52 Week Low
- HBT $19.46
- ZYME $9.03
- 52 Week High
- HBT $26.86
- ZYME $17.70
- Technical
- Relative Strength Index (RSI)
- HBT 63.91
- ZYME 70.16
- Support Level
- HBT $24.31
- ZYME $13.48
- Resistance Level
- HBT $25.76
- ZYME $14.68
- Average True Range (ATR)
- HBT 0.68
- ZYME 0.66
- MACD
- HBT 0.14
- ZYME 0.20
- Stochastic Oscillator
- HBT 96.22
- ZYME 93.49
About HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking.
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.